About the Company
We do not have any company description for Inhibikase Therapeutics, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics Reports Q2 2025 Financials and Progress
Inhibikase Therapeutics, Inc. ( ($IKT) ) has released its Q2 earnings. Here is a breakdown of the information Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ('Inhibikase” or 'Company”), a clinical-stage pharmaceutical company developing ...
Inhibikase Therapeutics Reports Q2 2025 Financial Results
Inhibikase Therapeutics ( ($IKT) ) just unveiled an announcement. On August 14, 2025, Inhibikase Therapeutics announced its financial results for ...
Here's Why Inhibikase Therapeutics, Inc. (IKT) Is a Great 'Buy the ...
Inhibikase Therapeutics, Inc. (IKT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern ...
Inhibikase Therapeutics Announces Closing of up to $275 Million ...
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company developing Abelson Tyrosine Kinase inhibitor therapeutics for Cardiopulmonary and Neurodegenerative disease.
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 ...
The conference call can be accessed by dialing 1-877-407-0789 (United States) or 1-201-689-8562 (International) and referencing Inhibikase Therapeutics.
Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline ...
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders.
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q4 2023 Earnings Call Transcript
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q4 2023 Earnings Call Transcript March 28, 2024 Inhibikase Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of ...
Inhibikase Therapeutics, Inc. (IKT) Upgraded to Buy: What Does ... - Nasdaq
Investors might want to bet on Inhibikase Therapeutics, Inc. (IKT), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in ...
Inhibikase Therapeutics Inc Shares Fall 2.0% Below Previous 52 ... - Nasdaq
Inhibikase Therapeutics Inc (IKT) shares closed 2.0% lower than its previous 52 week low, giving the company a market cap of $40M. The stock is currently down 76.8% year-to-date, down 83.7% over ...
Inhibikase Therapeutics Reports Third Quarter 2021 Financial Results ...
BOSTON and ATLANTA, Nov. 15, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of ...
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q4 2023 Earnings Call ...
Published on April 2, 2024 at 10:25 am by Insider Monkey Transcripts in News, Transcripts Inhibikase Therapeutics, Inc. (NASDAQ: IKT) Q4 2023 Earnings Call Transcript March 28, 2024 ...
Similar Companies
Loading the latest forecasts...